
Opinion|Videos|December 3, 2024
Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- PIRA represents MS progression without clinical relapses, impacting patients' quality of life by contributing to disability accumulation.
- Unlike RAW, PIRA reflects insidious progression, often undetected by traditional relapse-focused assessments.
Panelists discuss how progression independent of relapse activity (PIRA) in multiple sclerosis (MS) represents continuous neurological decline unrelated to inflammatory events, distinct from relapse-associated worsening (RAW). Recent ECTRIMS 2024 presentations emphasized standardized evaluation methods to better understand disease progression and improve patient management strategies.
Advertisement
Video content above is prompted by the following:
- Cognition and PIRA in MS have received a lot of attention in recent years.
- Please provide an overview of PIRA and its potential impact on a patient’s quality of life.
- How is PIRA different from RAW?
- How is PIRA evaluated? Discuss presentations from ECTRIMS 2024 by Muller and others about standardization of PIRA evaluation and why it might matter.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
4
Highlighting Gaps in Testing and Diagnosis for Fragile X Syndrome: Craig A. Erickson, MD
5


















